Pharmascience unit Pendopharm has entered an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market.

Pendopharm will be responsible for securing regulatory approval and overseeing the commercialisation of the product in the country.

Neither companies has disclosed the financial terms of the deal.

Ascendis Pharma executive vice-president and chief commercial officer Camilla Harder Hartvig stated: “We are delighted to partner with Pendopharm to bring TransCon PTH to Canada, contributing to our shared goal of making a meaningful difference in the lives of patients living with chronic hypoparathyroidism.”

A parathyroid hormone (PTH) replacement therapy, TransCon PTH is aimed at treating chronic hypoparathyroidism, a rare endocrine disorder characterised by low or inadequate levels of PTH.

The therapy has already secured approval in the European Union, the European Economic Area and Great Britain under the brand name YORVIPATH, specifically for adult patients.

TransCon PTH is undergoing development for the same indication in the US, Japan and other international markets.

Pendopharm vice-president and GM Jad Isber stated: “This partnership represents Pendopharm's commitment to bringing innovative medicines that address unmet medical needs to Canadian patients.

“We look forward to working with Canadian endocrinologists to make TransCon PTH available to all patients who may benefit from it.”

In May 2024, Pendopharm announced the renewal of a distribution agreement with Anika Therapeutics for Cingal, Monovisc and Orthovisc up to 2030.